ADCT
ADC Therapeutics S.A. NYSE Listed May 18, 2020$3.76
Mkt Cap $478.2M
52w Low $1.23
67.5% of range
52w High $4.98
50d MA $4.01
200d MA $3.79
P/E (TTM)
-3.4x
EV/EBITDA
-5.9x
P/B
—
Debt/Equity
-2.4x
ROE
76.8%
P/FCF
-3.2x
RSI (14)
—
ATR (14)
—
Beta
1.95
50d MA
$4.01
200d MA
$3.79
Avg Volume
878.9K
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Biopole · Epalinges, V8 1066 · CH
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | TNS | -0.19 | -0.21 | -10.5% | 3.68 | +1.4% | +2.2% | +2.7% | -2.8% | — | — | — |
| Mar 10, 2026 | TNS | -0.32 | -0.04 | +87.5% | 4.80 | -1.2% | +1.7% | -10.9% | -5.1% | +2.2% | -2.6% | — |
| Nov 10, 2025 | TNS | -0.40 | -0.30 | +25.0% | 4.21 | -1.0% | -5.7% | +2.0% | +0.0% | -2.2% | +0.3% | — |
| Aug 12, 2025 | TNS | -0.36 | -0.50 | -38.9% | 2.94 | +1.4% | +5.1% | +3.2% | -1.9% | +3.5% | -4.0% | — |
| May 14, 2025 | TNS | -0.38 | -0.36 | +5.3% | 1.81 | +0.6% | -6.6% | +11.8% | +23.8% | -8.1% | -8.4% | — |
| Mar 27, 2025 | TNS | -0.35 | -0.29 | +17.1% | 1.52 | -2.6% | -2.0% | -5.4% | -4.3% | -1.5% | -7.5% | — |
| Nov 7, 2024 | TNS | -0.36 | -0.42 | -16.7% | 2.93 | +4.4% | +0.0% | +1.7% | -1.7% | -3.8% | -6.0% | — |
| Aug 6, 2024 | TNS | -0.44 | -0.38 | +13.6% | 2.92 | +1.0% | -6.2% | +2.6% | -5.3% | -2.6% | +9.7% | — |
| May 6, 2024 | TNS | -0.56 | -0.56 | +0.0% | 4.45 | -1.1% | +8.5% | -8.7% | +3.6% | -5.9% | -2.6% | — |
| Mar 13, 2024 | TNS | -0.47 | -1.03 | -119.1% | 3.90 | -1.5% | -4.1% | +1.1% | +16.7% | +5.9% | +1.3% | — |
| Nov 7, 2023 | TNS | -0.61 | -0.58 | +4.9% | 0.73 | +1.4% | -17.3% | -22.0% | +0.4% | +6.4% | +10.2% | — |
| Aug 8, 2023 | TNS | -0.44 | -0.58 | -31.8% | 1.60 | -2.5% | -6.2% | +7.3% | +3.1% | -4.8% | +1.3% | — |
| May 9, 2023 | AMC | -0.80 | -0.74 | +7.5% | 2.17 | +1.8% | +10.6% | +0.4% | -2.9% | +13.2% | -7.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.86 | $4.10 | +6.2% | +4.9% | -2.7% | +0.8% | -0.3% | -6.6% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.19 | -1.6% | -3.1% | -1.2% | +5.1% | -3.7% | -1.5% |
| Aug 13 | Guggenheim | Maintains | Buy → Buy | — | $2.94 | $2.98 | +1.4% | +5.1% | +3.2% | -1.9% | +3.5% | -4.0% |
| Jun 20 | RBC Capital | Maintains | Outperform → Outperform | — | $3.03 | $3.07 | +1.3% | -8.6% | -3.2% | +6.3% | -3.2% | -2.2% |
| Jun 13 | Guggenheim | Maintains | Buy → Buy | — | $3.67 | $3.57 | -2.7% | -2.5% | -5.6% | -3.6% | -7.1% | -8.6% |
| May 15 | RBC Capital | Maintains | Outperform → Outperform | — | $1.81 | $1.82 | +0.6% | -6.6% | +11.8% | +23.8% | -8.1% | -8.4% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.49 | $1.43 | -4.0% | -5.4% | -4.3% | -1.5% | -7.5% | -4.1% |
| Mar 31 | Guggenheim | Maintains | Buy → Buy | — | $1.49 | $1.43 | -4.0% | -5.4% | -4.3% | -1.5% | -7.5% | -4.1% |
| Mar 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.75 | $1.75 | +0.0% | +5.1% | -6.0% | -0.6% | +7.6% | -4.3% |
| Feb 24 | Stephens & Co. | Maintains | Overweight → Overweight | — | $1.63 | $1.72 | +5.5% | -1.8% | -2.5% | +3.8% | -2.5% | +11.4% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.02 | $2.05 | +1.5% | -4.0% | +3.1% | -4.0% | -2.1% | -8.5% |
| Dec 12 | Guggenheim | Maintains | Buy → Buy | — | $2.22 | $2.31 | +4.1% | -10.8% | -4.5% | +5.8% | +6.5% | -10.3% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.48 | $3.37 | -3.2% | -36.2% | -10.8% | -4.5% | +5.8% | +6.5% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.74 | $2.77 | +1.1% | +2.6% | -5.3% | -2.6% | +9.7% | +0.4% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $2.92 | $2.95 | +1.0% | -6.2% | +2.6% | -5.3% | -2.6% | +9.7% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.45 | $4.40 | -1.1% | +8.5% | -8.7% | +3.6% | -5.9% | -2.6% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.39 | $4.39 | +0.0% | -0.5% | +1.6% | +11.7% | -4.0% | -0.8% |
| Mar 14 | RBC Capital | Maintains | Outperform → Outperform | — | $3.90 | $3.84 | -1.5% | -4.1% | +1.1% | +16.7% | +5.9% | +1.3% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.82 | $4.81 | -0.2% | +3.7% | -0.6% | -9.5% | -1.1% | +0.0% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $4.68 | $4.76 | +1.7% | +9.8% | -2.5% | -3.0% | -0.6% | +0.6% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.29 | $5.43 | +2.6% | -8.9% | -2.7% | +4.3% | -4.3% | +9.8% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.70 | $0.75 | +6.6% | +1.0% | +1.9% | -1.9% | +3.8% | -1.8% |
| Nov 9 | TD Cowen | Downgrade | Outperform → Market Perform | — | $0.60 | $0.59 | -1.5% | -22.0% | +0.4% | +6.4% | +10.2% | +6.2% |
| Nov 8 | RBC Capital | Maintains | Outperform → Outperform | — | $0.73 | $0.73 | +1.4% | -17.3% | -22.0% | +0.4% | +6.4% | +10.2% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.78 | $0.80 | +3.2% | +3.2% | -4.0% | -5.1% | -1.2% | +12.3% |
| Sep 12 | RBC Capital | Maintains | Outperform → Outperform | — | $1.04 | $1.00 | -3.8% | -8.2% | -3.2% | -5.6% | -6.1% | -5.4% |
| Aug 10 | JP Morgan | Upgrade | Underweight → Neutral | — | $1.50 | $1.56 | +4.0% | +7.3% | +3.1% | -4.8% | +1.3% | -9.4% |
| Aug 9 | RBC Capital | Maintains | Outperform → Outperform | — | $1.60 | $1.56 | -2.5% | -6.2% | +7.3% | +3.1% | -4.8% | +1.3% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.32 | +0.8% | -1.5% | -2.3% | -1.6% | +3.2% | +15.6% |
| Jul 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.37 | $1.95 | -17.7% | -21.9% | -18.4% | +2.6% | -2.6% | +4.0% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.29 | $2.28 | -0.4% | -0.4% | -4.4% | -1.8% | -4.2% | -2.4% |
| May 10 | RBC Capital | Maintains | Outperform → Outperform | — | $2.17 | $2.21 | +1.8% | +10.6% | +0.4% | -2.9% | +13.2% | -7.9% |
| Apr 24 | BofA Securities | Downgrade | Neutral → Underperform | — | $2.30 | $2.08 | -9.6% | -14.8% | +0.0% | +0.0% | -1.0% | +0.0% |
| Feb 13 | RBC Capital | Maintains | Outperform → Outperform | — | $4.40 | $4.45 | +1.1% | -1.8% | +2.8% | -0.2% | -2.5% | +0.7% |
| Jan 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.73 | $4.85 | +2.5% | -1.1% | +1.3% | -0.4% | +7.0% | -2.6% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.59 | $3.47 | -3.3% | -3.9% | +0.9% | +2.0% | +2.3% | +19.6% |
| Nov 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.10 | $4.11 | +0.2% | +1.5% | +6.0% | -2.3% | -7.0% | -2.2% |
| Nov 9 | BofA Securities | Downgrade | Buy → Neutral | — | $4.14 | $4.00 | -3.4% | -3.1% | -0.2% | +2.5% | +1.5% | +6.0% |
| Nov 9 | RBC Capital | Maintains | Outperform → Outperform | — | $4.14 | $4.00 | -3.4% | -3.1% | -0.2% | +2.5% | +1.5% | +6.0% |
| Sep 21 | JP Morgan | Maintains | Overweight → Overweight | — | $5.29 | $5.13 | -3.0% | -4.2% | -0.4% | -3.2% | -4.7% | +3.4% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.25 | $5.49 | +4.6% | +4.4% | -3.5% | -4.2% | -0.4% | -3.2% |
| Sep 9 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $6.52 | $6.08 | -6.7% | -5.4% | -2.8% | -5.0% | -1.6% | -3.0% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.42 | $8.19 | -2.7% | -11.4% | +3.8% | -1.4% | -3.9% | -2.7% |
| Aug 10 | RBC Capital | Maintains | Outperform → Outperform | — | $7.97 | $8.13 | +2.0% | +1.3% | +0.6% | +26.8% | -9.9% | -2.7% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.31 | $10.33 | +0.2% | -8.7% | -3.2% | -1.9% | -5.9% | -3.7% |
| May 10 | RBC Capital | Maintains | Outperform → Outperform | — | $7.81 | $8.01 | +2.6% | +1.0% | -12.2% | +0.6% | +6.0% | -3.4% |
| May 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.81 | $8.01 | +2.6% | +1.0% | -12.2% | +0.6% | +6.0% | -3.4% |
| Apr 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.15 | $13.47 | +2.4% | +6.5% | +3.6% | -2.3% | -5.1% | -1.9% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.77 | $15.00 | +1.6% | -4.7% | -0.6% | -0.6% | +5.6% | -2.8% |
| Feb 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $15.89 | $15.88 | -0.1% | +4.8% | -4.7% | -0.8% | +2.4% | +1.5% |
No insider trades available.
8-K · 2.02
!! High
ADC Therapeutics S.A. -- 8-K 2.02: Earnings Results
ADC Therapeutics reported Q1 2026 financial results, with the company's operational performance and financial condition details available through its May 4 press release for investor evaluation.
May 4
8-K
Unknown — 8-K Filing
ADCT's strong $261.3M cash position funds operations through 2028, but near-term stock sentiment depends on LOTIS-5 Phase 3 results due mid-2026, making clinical data timing critical for investor confidence.
Mar 10
8-K · 1.01
!! High
ADC Therapeutics SA -- 8-K 1.01: Material Agreement
ADC Therapeutics amended its royalty agreement with HealthCare Royalty Management, which has provided $300 million in cumulative funding, potentially affecting the company's financial obligations and cash flow structure.
Feb 23
Data updated apr 24, 2026 10:54am
· Source: massive.com